Omega-3 fatty acid supplementation in advanced kidney disease

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), which are obtained primarily from dietary sources such as coldwater fish, have diverse and potent mediating effects on the immune, inflammatory, and metabolic pathways, signal transduction, and cell membrane physiology. N-3 PUFA are increasingly being studied for their clinical benefits in a variety of medical conditions, some of which are relevant to individuals with advanced chronic kidney disease (CKD). These include, among others, renoprotection in IgA nephropathy, cardioprotective effects via a variety of mechanisms including blood pressure and triglyceride reduction, maintenance of dialysis access patency, sparing of inflammation-associated muscle loss, and even mortality. However, further confirmatory work needs to be performed before establishing formal intake recommendations and dosing goals for advanced CKD patients. In the meantime, the current American Heart Association n-3 PUFA intake guidelines can be applied to CKD patients, especially given n-3 PUFA's potential benefits and negligible risk profile. Over time, it will be incumbent upon the nephrology community to more clearly define the utility and optimal dosing of n-3 PUFA in CKD patients with advanced disease via randomized clinical trials.

Original languageEnglish
Pages (from-to)396-400
Number of pages5
JournalSeminars in Dialysis
Volume23
Issue number4
DOIs
StatePublished - Jul 2010

Fingerprint

Omega-3 Fatty Acids
Kidney Diseases
Chronic Renal Insufficiency
Cell Physiological Phenomena
Nephrology
Metabolic Networks and Pathways
Unsaturated Fatty Acids
Immunoglobulin A
Dialysis
Signal Transduction
Fishes
Triglycerides
Randomized Controlled Trials
Maintenance
Cell Membrane
Guidelines
Blood Pressure
Inflammation
Muscles
Mortality

ASJC Scopus subject areas

  • Nephrology

Cite this

Omega-3 fatty acid supplementation in advanced kidney disease. / Friedman, Allon.

In: Seminars in Dialysis, Vol. 23, No. 4, 07.2010, p. 396-400.

Research output: Contribution to journalArticle

@article{6126a3b85daf4b909cfbb7f40f346789,
title = "Omega-3 fatty acid supplementation in advanced kidney disease",
abstract = "Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), which are obtained primarily from dietary sources such as coldwater fish, have diverse and potent mediating effects on the immune, inflammatory, and metabolic pathways, signal transduction, and cell membrane physiology. N-3 PUFA are increasingly being studied for their clinical benefits in a variety of medical conditions, some of which are relevant to individuals with advanced chronic kidney disease (CKD). These include, among others, renoprotection in IgA nephropathy, cardioprotective effects via a variety of mechanisms including blood pressure and triglyceride reduction, maintenance of dialysis access patency, sparing of inflammation-associated muscle loss, and even mortality. However, further confirmatory work needs to be performed before establishing formal intake recommendations and dosing goals for advanced CKD patients. In the meantime, the current American Heart Association n-3 PUFA intake guidelines can be applied to CKD patients, especially given n-3 PUFA's potential benefits and negligible risk profile. Over time, it will be incumbent upon the nephrology community to more clearly define the utility and optimal dosing of n-3 PUFA in CKD patients with advanced disease via randomized clinical trials.",
author = "Allon Friedman",
year = "2010",
month = "7",
doi = "10.1111/j.1525-139X.2010.00748.x",
language = "English",
volume = "23",
pages = "396--400",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Omega-3 fatty acid supplementation in advanced kidney disease

AU - Friedman, Allon

PY - 2010/7

Y1 - 2010/7

N2 - Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), which are obtained primarily from dietary sources such as coldwater fish, have diverse and potent mediating effects on the immune, inflammatory, and metabolic pathways, signal transduction, and cell membrane physiology. N-3 PUFA are increasingly being studied for their clinical benefits in a variety of medical conditions, some of which are relevant to individuals with advanced chronic kidney disease (CKD). These include, among others, renoprotection in IgA nephropathy, cardioprotective effects via a variety of mechanisms including blood pressure and triglyceride reduction, maintenance of dialysis access patency, sparing of inflammation-associated muscle loss, and even mortality. However, further confirmatory work needs to be performed before establishing formal intake recommendations and dosing goals for advanced CKD patients. In the meantime, the current American Heart Association n-3 PUFA intake guidelines can be applied to CKD patients, especially given n-3 PUFA's potential benefits and negligible risk profile. Over time, it will be incumbent upon the nephrology community to more clearly define the utility and optimal dosing of n-3 PUFA in CKD patients with advanced disease via randomized clinical trials.

AB - Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFA), which are obtained primarily from dietary sources such as coldwater fish, have diverse and potent mediating effects on the immune, inflammatory, and metabolic pathways, signal transduction, and cell membrane physiology. N-3 PUFA are increasingly being studied for their clinical benefits in a variety of medical conditions, some of which are relevant to individuals with advanced chronic kidney disease (CKD). These include, among others, renoprotection in IgA nephropathy, cardioprotective effects via a variety of mechanisms including blood pressure and triglyceride reduction, maintenance of dialysis access patency, sparing of inflammation-associated muscle loss, and even mortality. However, further confirmatory work needs to be performed before establishing formal intake recommendations and dosing goals for advanced CKD patients. In the meantime, the current American Heart Association n-3 PUFA intake guidelines can be applied to CKD patients, especially given n-3 PUFA's potential benefits and negligible risk profile. Over time, it will be incumbent upon the nephrology community to more clearly define the utility and optimal dosing of n-3 PUFA in CKD patients with advanced disease via randomized clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=77955239437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955239437&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2010.00748.x

DO - 10.1111/j.1525-139X.2010.00748.x

M3 - Article

VL - 23

SP - 396

EP - 400

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 4

ER -